Kunhwa Kim1, Elias Jabbour1, Nicholas J Short1, Partow Kebriaei2, Hagop Kantarjian1, Farhad Ravandi3. 1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. 2. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. fravandi@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies. RECENT FINDINGS: The advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. To avoid toxicity from the historical treatment strategies, a more individualized, targeted approach to therapy including detection and monitoring of measurable residual disease (MRD) has become of interest. The treatment of patients with Ph+ ALL has been rapidly evolving with a more individualized, targeted treatment and use of TKIs and novel therapy.
PURPOSE OF REVIEW: Over the past two decades, tyrosine kinase inhibitors (TKIs) have changed the management of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and this has led to significant improvement in their outcome. In this review, we will provide an overview of the current understanding of treatment of Ph+ ALL focusing on TKIs, alloHSCT, and novel therapies. RECENT FINDINGS: The advent of more potent TKIs and the novel therapeutic options including blinatumomab, inotuzumab ozogamicin, and CD19 CAR-T therapy has changed the role of allogeneic hematopoietic stem cell transplant (alloHSCT) and intensive chemotherapy. To avoid toxicity from the historical treatment strategies, a more individualized, targeted approach to therapy including detection and monitoring of measurable residual disease (MRD) has become of interest. The treatment of patients with Ph+ ALL has been rapidly evolving with a more individualized, targeted treatment and use of TKIs and novel therapy.
Authors: G Götz; H J Weh; T A Walter; R Kuse; K Kolbe; G Dölken; K P Hellriegel; D Hoelzer; D K Hossfeld Journal: Ann Hematol Date: 1992-02 Impact factor: 3.673
Authors: Beate Gleissner; Nicola Gökbuget; Claus R Bartram; Bart Janssen; Harald Rieder; Johannes W G Janssen; Christa Fonatsch; Axel Heyll; Dimitris Voliotis; Joachim Beck; Thomas Lipp; Gerd Munzert; Jürgen Maurer; Dieter Hoelzer; Eckhard Thiel Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: Vinod Pullarkat; Marilyn L Slovak; Kenneth J Kopecky; Stephen J Forman; Frederick R Appelbaum Journal: Blood Date: 2007-12-21 Impact factor: 22.113
Authors: Anthony V Moorman; Lucy Chilton; Jennifer Wilkinson; Hannah M Ensor; Nick Bown; Stephen J Proctor Journal: Blood Date: 2009-11-06 Impact factor: 22.113